Chemical Property of Binimetinib
Chemical Property:
- Melting Point:>203oC (dec.)
- PKA:14.20±0.10(Predicted)
- PSA：91.90000
- Density:1.67
- LogP:3.65910
- Storage Temp.:-20°C
- Solubility.:Soluble in DMSO (up to at least 25 mg/ml)
- XLogP3:3.1
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:6
- Exact Mass:440.02956
- Heavy Atom Count:27
- Complexity:521
- Purity/Quality:
-
99%, *data from raw suppliers
MEK162 *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
- Recent ClinicalTrials:Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial
- Recent EU Clinical Trials:A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI?PD-1 THERAPY
- Recent NIPH Clinical Trials:Addition of binimetinib after refractory to encorafenib and cetuximab in patients with BRAF V600E-mutatnt metastatic colorectal cancer
-
Description
Binimetinib (606143-89-9) is a potent (IC50?= 12 nM) and selective allosteric inhibitor of MEK1/2.1,2?Recently approved by the FDA for treatment of melanoma in combination with Encorafenib. Binimetinib has had limited success as monotherapy but has shown promise in combination with other chemotherapeutic agents.3-5
-
Uses
MEK 162 is a MEK1/2 inhibitor allowing it to be a effective anti-cancer medication.
